Posted by Michael Wonder on 22 Mar 2017
NICE terminates four single technology assessments
22 March 2017 - Appraisals terminated as a result of four sponsors deciding not to submit evidence.
The terminated single technology assessments are:
- TA434 - Elotuzumab (Empliciti) for patients with previously treated multiple myeloma (BMS)
- TA435 - Tenofovir alafenamide fumarate (Vemlidy) for patients with chronic hepatitis B virus infection (Gilead)
- TA436 - Bevacizumab (Avastin) for patients with EGFR mutation-positive non-small-cell lung cancer (Roche)
- TA437 - Ibrutinib (Imbruvica) for use in combination with bendamustine hydrochloride and rituximab for patients with relapsed or refractory chronic lymphocytic leukaemia after the use of systemic therapy (Janssen)
